Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) EBITDA (2020 - 2026)

Edgewise Therapeutics has reported EBITDA over the past 7 years, most recently at -$49.9 million for Q1 2026.

  • Quarterly results put EBITDA at -$49.9 million for Q1 2026, down 22.36% from a year ago — trailing twelve months through Mar 2026 was -$176.7 million (down 21.98% YoY), and the annual figure for FY2025 was -$167.5 million, down 25.5%.
  • EBITDA reached -$49.9 million in Q1 2026 per EWTX's latest filing, up from -$50.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$16.1 million in Q1 2022 and bottomed at -$50.2 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$29.6 million (2023), compared with a mean of -$30.5 million.
  • The largest annual shift saw EBITDA plummeted 134.07% in 2022 before it fell 14.59% in 2025.
  • Over 5 years, EBITDA stood at -$18.6 million in 2022, then plummeted by 59.32% to -$29.6 million in 2023, then plummeted by 36.03% to -$40.3 million in 2024, then decreased by 24.69% to -$50.2 million in 2025, then rose by 0.59% to -$49.9 million in 2026.
  • Business Quant data shows EBITDA for EWTX at -$49.9 million in Q1 2026, -$50.2 million in Q4 2025, and -$40.2 million in Q3 2025.